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Table 1. Descriptive statistics for substance abusers hospitalized with influenza, 2013-2014. 
Substance Abuse 
Characteristic Yes (N = 61) No (N =900) p 
Demographics    
Age (years)1 52.44 ± 11.2 66.48 ± 19.1 <0.001 
Sex2   0.0375 
     Female 4.9 (27)3 95.1 (521)  
     Male 8.2 (34) 91.8 (379)  
Race    
     Non- Hispanic White 3.6 (22) 96.4 (594) <0.001 
     Non-Hispanic  Black 13.0 (25) 87.5 (175) <0.001 
     Hispanic 9.6 (11) 90.4 (104) 0.1315 
     Other 10.0 (3) 90.0 (27) 0.4045 
Flu Type   0.0896 
     Type A 7.0 (55) 93.0 (734)  
     Type B 4.0 (6) 96.5 (166)  
    
Illness Severity Measures    
Length of Stay (days) 6.98 ± 7.6 5.93 ± 9.1 0.3072 
Received Antiviral Treatment   0.8526 
     Yes 80.3 (49) 79.3 (714)  
     No 19.7 (12) 20.7 (186)  
Pneumonia Co-Infection   0.5506 
    Yes 7.5 (10) 6.2 (123)  
    No 92.5 (51) 93.8 (777)  
ICU Admission        0.0331 
    Admitted 10.5 (15) 89.5 (128)  
    Not Admitted 5.7 (46) 94.3 (756)  
Mechanical Ventilation    
    Yes 13.9 (9) 86.2 (56) 0.0161 
    No 5.7 (51) 94.3 (840)  
Outcome    
    Lived 3.5 (59) 94.3 (848) 0.4423 
    Died 1.6 (1) 96.7 (31)  
    
Risk Factors    
Vaccine   0.0594 
    Yes 4.9 (23) 95.1 (448)  
    No 7.9 (37) 92.1 (432)  
Body mass index (kg/m2) 28.42 ± 7.0 29.96 ± 9.1 0.1384 
Smoking Status   <0.001 
     Current 19.1 (49) 80.9 (208)  
     Former 1.9 (6) 98.1 (306)  
     Never Smoked 1.5 (6) 98.5 (386)  
Alcohol Abuse    
     Yes 23.3 (7) 76.7 (23) 0.0019 
     No 5.8 (54) 94.2 (877)  
4 
 
 
1. Continuous variables are presented as means ± standard deviation. 
2. Categorical variables are presented as row percent (n). 
3. Numbers/percent may not sum to N/100% due to missing data. 
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Table 2. Unadjusted and adjusted odds ratios for substance abuse and various characteristics. 
 
Characteristic N 
% Substance 
Abusers 
Unadjusted OR 
 (95% CI) 
Adjusted OR 
 (95% CI) 4 
Smoking Status     
     Current5 257 5.1 15.15 (6.39 – 35.97) 12.29 (5.15 – 29.32) † 
     Former 312 1.9 1.26 (0.40 – 3.95) 1.58 (0.49 – 5.03) † 
     Never Smoker 392 1.5 1.00 (reference) 1.00 (reference) 
Age (years)     
     Under 35 54 0.2 1.00 (reference) 1.00 (reference) 
     35-49 98 1.3 3.63 (0.78 – 16.86) 2.72 (0.56 –13.11)* 
     50-64 238 3.9 4.79 (1.12 – 20.51) 3.30 (0.74 – 14.61)* 
     65-79 235 0.9 1.04 (0.22 – 4.94) 0.93 (0.19 – 4.55)* 
     80 and over 336 0.1 0.08 (0.01 – 0.87) 0.12 (0.01 – 1.42)* 
Sex     
     Female 548 2.8 0.58 (0.34 – 0.97)  
     Male 413 3.5 1.00 (reference)  
Race     
     White 616 3.6 1.00 (reference) 1.00 (reference) 
     Black 200 12.5 3.86 (2.12 – 7.01) 2.45 (1.30 – 4.61)* 
     Hispanic 115 9.6 2.86 (1.35 – 6.07) 2.35 (1.06 – 5.22)* 
     Other     
Body mass index (kg/m2)     
     <25 387 2.7 1.00 (reference)  
     25 to <30 224 1.6 0.98 (0.52 – 1.92)  
     30+ 350 2.1 0.84 (0.46 – 1.54)  
Alcohol  Abuse 30 23.3 4.94 (2.03 – 12.03) 1.85 (0.73 – 4.65)* 
ICU Admission 143 1.6 1.93 (1.04 – 3.55)  
Pneumonia Co-Infection 133 7.5 1.24 (0.62 – 2.50)  
Mechanical Ventilation 65 15.0 2.65 (1.24 – 5.65)  
Having Flu Vaccine 471 2.5 0.60 (0.25 – 1.03)  
     
Health Conditions     
Any Lung Condition 252 2.1 1.40 (0.81 – 2.45) 1.64 (0.85 – 3.16)* † 
     Asthma 218 12.4 2.95 (1.74 – 5.01) 2.01 (1.12 – 3.59)* † 
Any Cardiovascular 
Disease 404 1.4 0.35 (0.19 – 0.66) 0.69 (0.34 – 1.41)* † 
     Atrial Fibrillation 121 1.7 0.22 (0.05 – 0.92) 0.70 (0.16 – 3.14)* † 
     Coronary Artery Dis. 179 1.1 0.14 (0.03 – 0.57) 0.23 (0.05 – 0.97)* † 
     Congestive Heart Fail 144 2.9 0.38 (0.14 – 1.07) 0.62 (0.21 – 1.85)* † 
Any Metabolic Disorder 411 1.8 0.49 (0.28 – 0.88) 0.61 (0.33 – 1.12)* † 
     Thyroid dysfunction 161 1.7 0.24 (0.08 – 0.79) 0.39 (0.12 – 1.32)* † 
     Kidney Disease 153 3.3 0.45 (0.18 – 1.15) 0.84 (0.31 – 2.26)* † 
Immunosuppressed 171 1.8 1.87 (1.04 – 3.36) 1.74 (0.96 – 3.16) † 
     AIDS 3 66.7 30.47 (2.72 – 341)  
     HIV 27 22.2 4.57 (1.78 – 11.78) 3.65 (1.40 – 9.48) † 
     Liver Disease 52 38.5 13.23 (6.97 – 25.1) 10.79(5.19 22.42)* † 
6 
 
 
4. Characteristics without adjusted odds ratios reported had no significant independent 
association with age and/or smoking. Odds ratio adjustments were made according to the 
key below: 
* Designates adjustment for smoking. 
† Designates adjustment for age. 
 
5. Significant odds ratios are highlighted in darker gray within the table. 
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Table 3. Relative risk of influenza-associated hospitalization for substance abusers. 
  
SUBSTANCE ABUSE  RELATIVE RISK  95% CI 
6.35% OF STUDY POPULATION 
1.80% OF CT POPULATION OVERALL 
3.53 2.78 – 4.51 
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Table 4. Descriptive statistics for current, former, and never smokers hospitalized with influenza, 
2013-2014. 
 Smokers    
Characteristic Current (N = 257) Former (N =312) Never (N =392)  p 
Demographics     
Age (years)6 53.67 ± 21.2 72.72 ± 15.4 67.07 ± 21.2 <0.001 
Sex7    0.0246 
     Female 24.8 (136)8 30.7 (168) 44.5 (244)  
     Male 29.3 (121) 34.9 (144) 35.8 (148)  
Race     
     Non-Hispanic White 20.6 (127) 38.0  (234) 41.4 (255) <0.001 
     Non-Hispanic Black 41.5 (83) 24.0 (48) 34.5 (69) <0.001 
     Hispanic 30.4 (35) 22.6 (26) 50.0 (54) 0.0552 
     Other 40.0 (12) 13.3 (4) 46.7 (14) 0.0553 
Flu Type    0.1420 
     Type A 28.0 (221) 31.6 (249) 40.4 (319)  
     Type B 20.9 (36) 36.6 (63) 42.4 (73)  
     
Illness Severity Measures     
Length of Stay (days) 5.40 ± 6.2 5.89 ± 5.7 6.49 ± 12.3 0.3136 
Received Antiviral Treatment    0.9769 
     Yes 79.8 (205) 79.5 (248) 79.1 (310)  
     No 20.2 (52) 20.5 (64) 20.9 (82)  
Pneumonia Co-Infection    0.5505 
     Yes 24.0 (33) 30.1 (40) 45.1 (60)  
     No 27.1 (224) 32.9 (272) 40.1 (332)  
ICU Admission         0.4413 
    Admitted 29.4 (42) 35.7 (51) 35.0 (50)  
    Not Admitted 26.8 (215) 32.5 (261) 40.7 (326)  
Mechanical Ventilation    0.0836 
    Yes 38.5 (25) 27.7 (18) 33.9 (22)  
    No 25.8 (230) 32.8 (292) 41.4 (369)  
Outcome    0.4738 
    Lived 27.0 (245) 32.5 (295) 40.5 (367)  
    Died 18.8 (6) 31.3 (10) 50.0 (16)  
     
Risk Factors     
Vaccine    0.6339 
    Yes 27.4 (129) 31.0 (146) 41.6 (196)  
    No 26.0 (122) 33.9 (159) 40.1 (188)  
Body mass index (kg/m2) 30.34 ± 8.6 29.86 ± 9.1 29.53 ± 9.18 0.5757 
Substance Abuse    <0.001 
     Yes 80.3 (49) 9.8 (6) 9.8 (6)  
     No 23.1 (208) 34.0 (306) 42.9 (386)  
Alcohol Abuse     
     Yes 83.3 (25) 6.7 (2) 10.0 (3) <0.001 
     No 24.9 (232) 33.3 (310) 41.8 (389)  
9 
 
 
6. Continuous variables are presented as means ± standard deviation. 
7. Categorical variables are presented as row percent (n). 
8. Numbers/percent may not sum to N/100% due to missing data. 
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Table 5. Health conditions significantly associated with smoking.  
 
Health Condition N 
% Current 
Smokers (n)9 
% Former 
Smokers (n)9 
% Never 
Smokers (n)9 
 
p 
      
Any Lung Condition 252 32.310 (83) 40.1 (125) 11.2 (44) <0.001 
     Asthma 218 30.4 (78) 18.0 (56) 21.4 (84) 0.0015 
     COPD 232  31.2 (82) 36.5 (114) 9.2 (36) <0.001 
Any Cardiovascular Disease 404 28.4 (73) 54.5 (170) 41.1 (161) <0.001 
     Atrial Fibrillation 121 3.5 (9) 18.9 (59) 13.5 (53) <0.001 
     Coronary Artery Disease 179 12.5 (32) 28.9 (90) 14.5 (57) <0.001 
     Congestive Heart Fail 144 10.5 (27) 20.2 (63) 13.8 (54) 0.0038 
Any Metabolic Disorder 411 38.5 (99) 51.0 (159) 39.0 (153) 0.0018 
     Thyroid dysfunction 161 10.5 (27) 22.4 (70) 16.3 (64) 0.0007 
Any Kidney Disease 153 9.3 (24) 18.6 (58) 18.1 (71) 0.0034 
     Renal Insufficiency 108  5.8 (15) 14.7 (46) 12.0 (47) 0.0031 
Dementia 82 1.6 (5) 10.3 (32) 11.5 (45) <0.001 
HIV 27 5.5 (14) 1.0 (3) 2.6 (10) 0.0051 
Immunosuppressive Therapy 48 2.0 (5) 6.1 (19) 6.1 (24) 0.0322 
Liver Disease 52 10.9 (28) 4.5 (14) 2.6 (10) <0.001 
 
9. Percent given reflects the prevalence of listed health condition among either current, 
former, or never smokers. Percents will not add to 100 across rows. 
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Table 6. Logistic regression model for smokers. 
 
Characteristic 
 Model (N=1585) 
Odds Ratio (95% CI) Beta (SE) p 
Age (years) 0.95 (0.94 – 0.96) -0.0546 (0.004) <0.001 
Female 0.67 (0.51 – 0.88) -0.4053 (0.138) 0.0034 
BMI 0.98 (0.96 – 0.99) -0.0211 (0.008) 0.0086 
Non-Hispanic Black 1.81 (1.29 – 2.53) 0.5922 (0.172) 0.0006 
Hispanic 0.79 (0.51 – 1.22) -0.2332 (0.221) 0.2903 
Outcome (death) 0.86 (0.35 – 2.12) -0.1530 (0.460) 0.7396 
ICU Admission 1.45 (0.98 – 2.16) 0.3720 (0.202) 0.0656 
Length of Stay 0.98 (0.96 – 1.00) -0.0212 (0.012) 0.0684 
    
COPD 4.34 (3.17 – 5.95) 1.4687 (0.161) <0.001 
Atrial Fibrillation 0.40 (0.18 – 0.89) -0.9249 (0.410) 0.0240 
Congestive Heart Failure 41.67 (3.92 – 442.95) 3.7297 (1.206) 0.0020 
Immunosuppressed Status 0.51 (0.35 – 0.74) -0.6814 (0.192) 0.0004 
HIV Positive 3.70 (1.60 – 8.52) 1.3070 (0.426) 0.0022 
Renal Disease 0.61 (0.40 – 0.94) -0.4884 (0.219) 0.0259 
Liver Disease 2.42 (1.34 – 4.36) 0.8822 (0.302) 0.0034 
    
Interaction terms    
Age*Congestive Heart Failure 0.95 (0.91 – 0.98) -0.0558 (0.017) 0.0013 
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Table 7. Relative risk of influenza-associated hospitalization for smokers. 
 
SMOKING  RELATIVE RISK  95% CI 
26.7% OF STUDY POPULATION 
18.4% OF CT POPULATION OVERALL 
1.72 
 
1.55 – 1.92 
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FIGURES 
 
Figure 1.  Adjusted odds ratios for selected conditions and substance abuse. 
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Figure 2. Age distribution of flu-associated hospitalization cases, stratified by substance abuse 
status. 
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Figure 3. Influenza-associated hospitalization by MMWR week, stratified by substance abuse 
status. 
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Figure 4. Visual representation of statistically significant odds ratios between smoking and select 
characteristics. 
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2. ABSTRACT 
 
INTRODUCTION: Globally, influenza is responsible for 3-5 million cases of severe illness 
annually. In the United States alone, it is estimated that flu-associated infections account for 3.1 
million hospitalized days per year. While the overall impact of flu is relatively well-studied, 
severe influenza is not well-characterized among the substance abuser and smoker populations.  
 
OBJECTIVES: This study characterizes the risks for and complications associated with serious 
influenza infection among the substance abuser and smoking populations within Connecticut. 
 
METHODS: Data were obtained via retrospective medical chart review. Cases were individuals 
within New Haven and Middlesex counties hospitalized with a positive influenza test during the 
2011-2012, 2012-2013, and 2013-2014 flu seasons. Smoking and substance use status were 
analyzed for associations with variables along three main categories: demographics, illness 
severity measures (e.g. ICU admission, death), and co-morbid conditions. Odds ratios were 
obtained for statistically significant associations. Logistic regression was used to model risks of 
smoking. 
 
RESULTS: Of the 961 cases, 61 (6.3%) were substance abusers and 257 (26.7%) were current 
smokers. On average, substance abusers were 8 years younger upon admission, 1.72 (95% CI 
1.03 – 2.94) times more likely to be male than female, 3.86 (95% CI 2.12 – 7.01) times more 
likely to be black than non-Hispanic white, and faced the highest burden of flu in January. 
Substance abusers had greater odds of being admitted to the ICU (OR=1.93) and requiring 
mechanical ventilation (OR=2.65). Smoking status was not significantly associated with 
increases in illness severity but smokers were at increased risk for COPD (OR=4.34), liver 
disease (OR=2.42), and HIV (OR=3.70). Overall, substance abusers have 3.53 (95% CI 2.78 – 
4.51) times the risk of being hospitalized with an influenza infection than non-drug users, twice 
the risk of influenza-associated hospitalization for smokers (RR=1.72).  
 
CONCLUSIONS: Influenza hospitalizations are mildly to moderately more severe among 
substance users. Future directions could include targeted flu vaccine interventions for this 
population, through programs such as syringe exchange and substance abuse treatment.  
18 
 
3. INTRODUCTION 
 
3.1 Investigation Objectives 
The objective of this study was to characterize the population of substance abusers and 
smokers hospitalized with influenza-associated illnesses in Connecticut, and to assess whether 
substance use and smoking have an effect on illness severity and outcome. 
 
3.2 The Burden of Influenza 
 Influenza is a ubiquitous seasonal viral respiratory infection, with an estimated attack rate 
of 5-10% among adults, and up to 30% in children. Globally, influenza infections result in 3-5 
million cases of severe illness and 250,000-500,000 deaths each year [1]. Influenza traditionally 
has not been the focus of global infectious disease efforts; nor do the annual epidemic cycles 
often reach the front page of the world news. However, surveillance and research into the disease 
is a necessary part of global public health for several reasons: the influenza virus infects multiple 
species, mutates rapidly, disproportionately affects young children and the elderly, and causes 
large losses in productivity and life-years among adults.  
 Within the United States, influenza is consistently responsible for substantial morbidity 
and mortality [2]. The Centers for Disease Control and Prevention (CDC) conducts annual 
surveillance on flu-related illness and hospitalization, deaths, and disease burden via data 
collection sites across the country [3]. Because the influenza virus readily mutates and 
pandemics occasionally occur, it is difficult to reliably estimate the impact of influenza on a 
year-to-year basis.  Researchers have relied on modeling techniques to predict seasonal severity, 
using data from mortality reports, hospitalizations, and other sources [4–6].  
Currently, the best form of preventive protection against influenza is the flu vaccine, 
changed yearly to reflect the strains predicted to have the highest impact. The World Health 
Organization (WHO) sets recommendations for the composition of the seasonal flu vaccine [7], 
and individual countries administer the vaccine according to their own guidelines. Though 
vaccine efficacy varies from season to season, it was estimated that the 2013-2014 vaccine 
averted 7.2 million cases of influenza-associated illnesses in the United States alone. 
Risk factors that influence flu outcomes and severity have been studied to varying 
degrees. Children, pregnant women, immunocompromised hosts, and residents of nursing homes 
have been shown to have increased risk of acquiring influenza [8]. Increased incidence is also 
seen among low socioeconomic groups and females [9].  
Health-risk behaviors also have the potential to be major risk factors for poor health 
outcomes, but the influence of risk behaviors on influenza is less well-studied. Among alcohol 
abusers, a large study using data from 2005-2012 found that heavy alcohol consumption was a 
risk factor for developing severe influenza infections [10]. There have been additional studies 
conducted in mice that have determined that ethanol consumption was associated with more 
severe influenza infections [11]. 
Substance abuse and addiction have great potential to cause increased illness morbidity 
and mortality, given the associations with long-term risky behaviors and both negative physical 
and mental health outcomes. This study seeks to explore the relationship between influenza 
severity, smoking, and substance abuse. 
 
 
 
19 
 
3.3 Smoking and Influenza 
The World Health Organization (WHO) cites the tobacco epidemic as one of the biggest 
public health threats the world has ever faced. Globally, it is estimated that over 1 billion people 
smoke [12, 13]. Over 5 million deaths per year are directly attributed to tobacco use, and it is 
estimated that nearly 50% of current tobacco users will die of tobacco-related illnesses [14].  
 Although smoking rates have declined over the years, as of 2012, an estimated 18.1% of 
all adults in the United States (approximately 42.1 million people) reported being current 
smokers [15]. On average, men smoke more than women (20.5% vs. 15.8%), and multi-race 
individuals and Alaskan Native/Native American individuals report the highest prevalence of 
smoking (26.1% and 21.8%, respectively). 4.3% of respondents reported using snuff and/or 
chewing tobacco for at least some days currently [16].  
 In 2013, the Behavioral Risk Factor Surveillance System (BRFSS) reported a 15.5% 
(95% CI 14.3-16.7) prevalence of current smokers among adults in Connecticut (n=1058) [17], a 
lower proportion of smokers than the national average. 10.1% report smoking every day, 5.4% 
report smoking some days, 28.2% report being former smokers, and 56.3% report never smoking 
[18]. Connecticut also reports a lower use of chewing tobacco/snuf/snus, with only 1.8% 
reporting that they use it at least some days [19]. 
 The risk of smoking on influenza outcome and severity is well-characterized. Smoking is 
associated with a number of respiratory illnesses, both chronic and acute [20]. A 1982 study 
established a link between smoking and increased risk of epidemic H1N1 [21], and estimated 
that among smokers with influenza, 40.6% of severe influenza cases were attributable to the risk 
behavior of smoking itself.  Prospective studies on student populations and the elderly estimate 
odds ratios of 4.1 – 4.4 for incidence of influenza among smokers [22, 23]. Smoking also seems 
to impact influenza vaccine efficacy as well: vaccinated smokers who lacked hemagglutination-
inhibition (HI) antibody prior to vaccination were significantly more susceptible to influenza 
than non-smokers, and immunity produced by the vaccine waned rapidly [24].  
 
3.4 Substance Abuse and Influenza 
A smaller—but no less significant—risk-taking population is illicit drug users: over 15 
million people abuse heroin and over 14 million individuals abuse cocaine worldwide. The 
National Survey on Drug Use and Health, conducted by the Center for Behavioral Health 
Statistics and Quality, reports on drugs, alcohol, and tobacco use in the civilian, non-
institutionalized population over 12 years of age in the United States. This survey reported 22.5 
million current substance abusers in the US. 620,000 individuals were current heroin users in 
2011 [25]. There is an estimated one million injection drug users (IDUs) in the United States as 
of 2007 [26]. In Connecticut, it is estimated that there are 66,000 individuals who abuse illicit 
drugs other than marijuana over the year of the survey (2013) [27]. 
A review of the literature was conducted to assess the existing evidence surrounding the 
influence of substance abuse behaviors on influenza risk. Searches were performed on PubMed 
and Google Scholar using the following keywords: intravenous, injection, injecting, IDU, drug, 
user, influenza, risk, substance abuse, illicit drug use.  
 There are very few studies that examine the risk of influenza for the substance abuser 
population. Most of the existing literature focuses on the increased risk of HIV, hepatitis B virus 
(HBV), and hepatitis C virus (HCV) among the substance abuser population, three infectious 
diseases associated with unsafe injection practices. Most of the influenza-related work focuses 
on influenza vaccines: while there is a lack of observational studies on vaccine efficacy in this 
20 
 
population, a few studies examine the effectiveness of influenza vaccines on IDUs by measuring 
seroconversion [40]. In one such study, 409 former IDUs, some of whom were HIV positive, 
were vaccinated against influenza. Both the HIV positive and HIV negative groups showed no 
significant changes in CD4 counts as a result of the vaccination, indicating that influenza 
vaccines may not impair immune function in this group and can be incorporated into regular 
preventive care for the population [28]. A similar study on former heroin users demonstrated that 
having a history of substance abuse did not affect immunogenicity of the influenza vaccine in 
both HIV positive and negative individuals [41]. A systematic review that sought to examine the 
effects of several different vaccines (including the influenza vaccine) was conducted, but only 
two studies were used in their analysis of flu vaccine efficacy. Again, the researchers concluded 
that there was little to no adverse immunological effect of vaccinating the IDU population [40]. 
An in vitro study concluded that methamphetamine reduced influenza viral reproduction [29]. 
Little is known about the burden associated with severe influenza among substance abusers, on 
both a molecular and epidemiological level.  
 
3.5 Potential Impact 
 This project aims to fill the knowledge gap surrounding substance abusers and influenza, 
and to provide evidence of the illness severity associated with smoking and substance abuse 
among influenza-associated hospitalization cases. The results of this study can be used to tailor 
treatment for these populations, make flu vaccination recommendations, and to raise awareness 
among clinicians that smokers and substance abusers may have unique health needs when it 
comes to upper respiratory infections. 
 
4. METHODS 
 
4.1 Data Collection 
Data were obtained from the Connecticut Emerging Infections Program (CTEIP), which 
serves as a population-based surveillance site for the Centers for Disease Control and Prevention 
(CDC)’s Weekly U.S. Influenza Surveillance Report [30]. The CDC’s Influenza Hospitalization 
Surveillance Network (FluSurv-NET) draws from these surveillance sites to estimate age-
specific influenza-related hospitalization rates and to characterize the population hospitalized 
with severe influenza.  
At the CTEIP site, data are collected each year during the flu season (October 1 – April 
30) on all individuals within the catchment area of New Haven and Middlesex Counties, who 
were hospitalized with a laboratory-confirmed positive influenza test [31]. An individual who 
meets the case definition for surveillance is also assessed, via a retrospective review of his or her 
medical record, for various demographic factors, over 72 other co-morbid health conditions, 
details on the duration and course of their influenza-related hospitalization, and their flu 
vaccination status.   
Although the CTEIP collects hospitalization data across all ages, for the purpose of this 
study pediatric cases (aged under 18 years upon hospital admission) were excluded. For the 
study’s characterization of substance abuser population hospitalized with influenza, data from 
the 2013-2014 flu season were used. In this dataset, substance abuse was classified as any note of 
illicit drug abuse, and recorded under “Other disease conditions,” “Other,” and filled in 
descriptively. Drug users who were noted to use marijuana exclusively were excluded from the 
substance abuse category.  
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To characterize the smoking population, data from 2011-12, 2012-13, and 2013-14 
surveillance seasons were used. Medical records for the 2013-2014 flu season were accessed via 
hospital records (both paper and electronic), MyChart on EpicCare EMR software (Epic Systems 
Corporation), or collected via hospital visits. Eighteen hospitals within Connecticut contributed 
to the dataset. Completed datasets for the 2011-2012 and 2012-2013 seasons were collected from 
CTEIP. Statistical analysis was conducted using SAS Version 9.3 (SAS Institute Inc, Cary, NC). 
 
4.2 Descriptive Statistics for Substance Abusers  
First, descriptive statistics for the sample were obtained, with the objective of comparing 
the substance abuse population to the general influenza-hospitalized population along three main 
areas: demographics, illness severity, and additional risk factors. The demographic variables 
examined were age, race, ethnicity, sex, and influenza type (A or B, with some subtype/strain 
data available). To facilitate analysis, race and ethnicity data were categorized as non-Hispanic 
white, non-Hispanic black, Hispanic, and other. Age was treated as a continuous variable for 
characterization purposes and in any modeling.  In the case of bivariate association testing, age 
was stratified into five groups: 18-35, 35-49, 50-64, 65-79, and 80 and over. Illness severity was 
assessed by examining length of hospital stay in days, whether or not an individual received 
antiviral treatment, whether or not an individual spent time in the ICU, whether or not a patient 
received mechanical ventilation or ECMO/bypass, whether the patient died during the 
hospitalization, and whether or not the patient had pneumonia. An individual was considered to 
have pneumonia if he or she had a discharge ICD-9 code indicating pneumonia of any origin 
(ICD-9 codes 480 – 486.xx). Lastly, the population was evaluated for the presence of additional 
risk factors: smoking status, alcohol abuse status, BMI, and whether or not a patient had received 
a flu vaccine prior to admission. Smoking status was stratified to three levels: current smokers, 
former smokers, and never smokers. Alcohol abuse was recorded only if there was direct 
mention of abuse, addiction, or the need for rehabilitation in the medical chart; it is likely that 
true alcohol abuse is underestimated in the study due to no recording of binge drinking behavior 
or sporadic alcohol misuse. 
 To test for significant differences between the substance abuser and general influenza-
hospitalized population with regards to continuous variables, the Student’s t-test was used with 
an α-level of 0.05. The Student’s t-test assumes a normal distribution and tests a null hypothesis 
that there is no statistically significant difference between two means. To verify the normality 
assumption, all continuous variables (age, BMI, and length of stay) were tested for normality. All 
continuous variables passed Cramer-von Mises and Anderson-Darling tests (p<0.005), indicating 
that the t-test was an appropriate statistical test. 
 Testing for significant differences between substance abuse and the general population 
with regards to categorical variables was performed using the chi-squared test, with a null 
hypothesis that there was no significant difference between the proportion of substance abusers 
and non-substance abusers with the characteristic of interest. The significance threshold for all 
chi-squared tests was also 0.05. 
To visualize the time course of influenza associated hospitalizations among substance 
abusers compared to the general population, an epidemic curve for the two populations was 
generated. The curve depicts the frequency of hospital admissions among substance abusers 
compared to non-substance abusers in one week intervals. To correspond with case reporting, 
number of admissions were totaled by MMWR week (weeks 39-52 in 2013 to weeks 1-17 in 
2014). 
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4.3 Risk Measures for Substance Abuse  
 After testing for associations between various characteristics and substance abuse status, 
odds ratios were obtained to describe the magnitude of risk.  Tests were performed for all 
variables included in the descriptive analysis, along with 72 health conditions (see Appendix 1 
for full list). A bivariate analysis approach, rather than modeling the data, was chosen to obtain 
risk measures due to the small sample size of substance abusers within the total population.  
Bivariate analysis was carried out using Maentel-Hanszel chi-square tests, which assumes 
a null hypothesis that the proportion of substance abusers with the characteristic of interest does 
not differ significantly from the proportion of non-substance abusers with the characteristic. The 
test also calculates an odds ratio, or the odds that substance abusers are more or less likely to 
have the characteristic of interest when compared to non-substance abusers. For tests of 
association in which fewer than five individuals were included per category, Fisher’s exact test 
was used with the same null hypothesis. Both of these tests were carried out with a significance 
threshold of p = 0.05.  
Variables that did not include a member of the substance abuse population (for example, 
history of Guillan-Barre syndrome), were excluded from analysis. Additionally, variables that for 
which there were only a few substance abusers were excluded due to low sample size. Tests were 
carried out to the 0.05 level of significance.  
Variables that were determined to be effect modifiers or confounders for specific 
outcomes were adjusted for in the analysis process. To determine confounding or effect 
modification, the relationship between substance abuse and the variable of interest was stratified 
along the levels of a third variable (the potential confounder). The Breslow-Day test of 
homogeneity was used to determine whether differences in stratified odds ratios existed.  
 To estimate the relative risk of hospitalization as a substance abuser, state and nationwide 
estimates of these risk behaviors were used. Public data were obtained from the Center for 
Behavioral Health Statistics’ National Survey on Drug Use and Health from the year 2013 to 
provide estimates of the number of substance abusers over the year in the state of Connecticut. 
For the purpose of risk estimates, the category “substance abuse other than marijuana” was used. 
The overall population in Connecticut as well as the population of New Haven and Middlesex 
counties were obtained from the US Census Bureau’s State and County Census QuickFacts [32]. 
A prevalence of substance abuse within Connecticut was calculated using the survey results and 
census population data. Assuming that the prevalence of substance abuse within Connecticut was 
equally distributed throughout the state, this prevalence was used to estimate the number of 
substance abusers that would be located within the catchment area of New Haven and Middlesex 
counties.  
 
4.4 Descriptive Statistics for Smoking Population 
Descriptive statistics for the smoking population were obtained using the methods 
detailed in section 2.2. For this analysis, smoking was stratified into three categories: current, 
former, and non-smokers. Like substance abusers, smokers were also assessed along three main 
areas: demographics, illness severity measures, and risk factors. 
Relative risk of influenza-associated hospitalization for smokers was determined using 
the methods in section 2.3. Data for smoking prevalence came from the 2013 Behavioral Risk 
Factor Surveillance System surveys. 
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4.5 Logistic Regression Modeling  
To better understand the relationship between smoking, demographics, co-morbid 
conditions, and illness severity during flu-association hospitalizations, data from the 2011-2014 
surveillance seasons were modeled using logistic regression. For the purposes of the model, 
smoking was transformed into a binary variable: current and non-smokers (which includes those 
who have never smoked, as well as those who no longer smoke but may be former smokers). 
Former and non-smokers exhibited similar age trends upon hospital admission and a similar 
profile of co-morbid conditions. Because of inconsistencies in reporting substance abuse in the 
2011-2012 and 2012-2013 flu season, substance abuse as a risk factor was excluded from model 
consideration. Additionally, because the alcohol abuse variable was suspected to underreport risk 
behaviors such as binge drinking, and because alcohol abuse significantly overlapped with 
smoking, this risk factor was also excluded from the model.  
Smoking status was designated as the binary response variable (smoking =1, nonsmoking 
=0). The explanatory variables for the full model were as follows: age, sex, BMI, race, length of 
stay, ICU admission, use of mechanical ventilation, use of ECMO, vaccine status prior to 
admission, type of flu, whether or not the case had pneumonia during hospitalization, and all co-
morbid health conditions listed in Appendix 1. 
 Selection of variables for the model was conducted using a backwards-elimination 
strategy starting with the full number of explanatory variables. Variables for which there were no 
smokers were immediately removed from the model. To compare goodness-of-fit between 
models when model selecting, the Aikake Information Criterion (AIC) score was used. Variable 
removals that resulted in an AIC score decrease of 2 or greater were considered significant, and 
the next iteration of the model was run without that variable. Variables were removed 
sequentially in this manner, starting with those with the highest p-values, until the AIC score did 
not decrease. Covariates that remained were considered in the final model. Because this was a 
model designed to explore associative relationships, covariates with p-values that did not meet 
the significance threshold (p<0.05) remained in the model if removal did not decrease the AIC 
score. 
 Of the covariates remaining, a correlation matrix was assembled for all variables. If two 
variables had a Spearman correlation coefficient > 0.2 (or < -0.2), indicating possible 
collinearity, an interaction term between the two variables was created and tested in the model. 
Interaction terms that further lowered the AIC score by 2 or more were added into the model. 
  
5. RESULTS 
 
5.1 2013-2014 Sample Characterization 
There were a total of 961 individuals over the age of eighteen included in the sample. The 
population was 56.5% female, 64.1% non-Hispanic white, with an average age of 64.6 (standard 
deviation ± 19.0) years. 471 individuals (49.0%) were hospitalized despite reporting receiving a 
flu vaccine sometime between September 2013 and admission. Median hospitalization time was 
4 days. Of those individuals, 257 (26.7%) reported being a current smoker, and an additional 312 
(32.5%) reported being a former smoker. 61 individuals (6.3%) were substance abusers.  
 
5.2 Substance Abusers 
The sample was split into those who were recorded as substance abusers (n=61) and those 
who had no record of substance abuse (n=900). Across Connecticut, substance abusers were 3.53 
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times more likely to be hospitalized for influenza-associated illness than non-substance abusers, 
and are at twice the risk of hospitalization when compared to smokers (see Tables 3 and 7). The 
full comparison between hospitalized substance abusers and non-substance abusers can be seen 
in Table 1. Of note, the average age of hospitalized substance abusers was 52.4 years, fourteen 
years younger than the average age of those who did not report substance abuse (66.5 years, 
p<0.001). Other significant differences were seen across race, with 12.5% of non-Hispanic 
blacks and 9.6% of Hispanics reporting substance abuse, compared to 3.6% of non-Hispanic 
whites (p<0.001 for non-Hispanic blacks; p=0.1315 for Hispanics). Almost twice the proportion 
of males reported substance abuse than females (8.2% and 4.9%, respectively, p = 0.0375).  
 Illness severity measures differed across both populations as well. Average length of stay 
among substance abusers was around one day longer than non-substance abusers, though this 
result was not statistically significant. Substance abusers reported a significantly greater 
frequency of ICU admissions (10.5% of ICU admissions were substance abusers, while only 
5.7% of regular hospitalizations were substance abusers, p=0.0331) and mechanical ventilation 
(13.9% of all incidences of mechanical ventilation were seen in substance abusers, p=0.0161). 
Pneumonia incidence, receipt of antiviral treatment, and survival outcomes during hospitalization 
were not significantly associated with substance abuse. 
 While there was no significant association between BMI and substance abuse, substance 
abusers had an overall lower proportion vaccinated against the flu than non-substance abusers, 
though this result is not statistically significant (p=0.0594). Additionally, substance abusers had a 
significantly higher frequency of engaging in other measured risk behaviors such as smoking and 
alcohol abuse. Forty-nine out of the 61 substance abusers were current smokers (80.3%), 
indicating that the majority of drug users engaged in multiple health-risk behaviors.  
 
5.2.1 Bivariate Analysis 
Data analysis to determine any associations between substance abuse and other collected 
variables was undertaken. All significant associations between substance abuse and their 
corresponding odds ratios are shown in Table 2.  
 
Smoking as a confounder 
Because a large proportion of substance abusers also reported smoking, and there is 
overwhelming evidence suggesting that smoking is associated with a number of harmful health 
outcomes, smoking was determined to be a potential confounder for health conditions analysis. 
The odds ratios for conditions that were independently associated with smoking and substance 
abuse were adjusted for to account for this confounding effect. Adjusted odds ratios are provided 
where applicable.  
 
Age as an effect modifier 
One concern in the analysis was that age could also be a possible effect modifier within 
this dataset, given that some of the health conditions analyzed are more common among certain 
age groups. Unadjusted substance abuse varied considerably across age groups, with those in the 
46-60 year range 4.79 times more likely to report substance abuse than individuals under 30. 
Age, when analyzed as a continuous variable, was independently associated with smoking and 
all co-morbid conditions of interest. 
 However, due to the small sample size of the substance abuse population (n=61), the 
study was not powered to conduct rigorous stratified analyses and present stratified odds ratios. 
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 To adjust for age, a logistic regression model was used to obtain odds ratios between 
substance abuse (outcome) and various co-morbid conditions (predictors), with age as a 
continuous predictor variable in the model. If the condition was also independently significantly 
associated with smoking, smoking was included as a predictor variable as well, resulting in odds 
ratios that were adjusted for both smoking status and age.  
 The age distribution of the substance abuse population versus the non-substance abuse 
population is depicted in Figure 2. Further descriptive information on the age distribution of 
substance abusers and the correlations between age and various health conditions are included in 
Appendix 2. 
 
Unadjusted and Adjusted Odds Ratios 
Most significantly substance abusers hospitalized with influenza-associated illness have 
12.29 [95% CI 5.15 – 29.32] times the odds of being current smokers than non-substance abusers 
of the same population. Substance abusers were 1.72 times more likely to be male, 2.45 times 
more likely to be non-Hispanic black, and 2.35 times more likely to be Hispanic (when 
compared to non-Hispanic whites). Substance abuse status did not significantly differ across age 
categories, though the highest frequency was seen among 50-64 year olds. 
 Substance abuse is also a risk factor for several illness severity measures, with substance 
users 1.93 [95% CI 1.04 – 3.55] times more likely to be admitted to the ICU and 2.65 [95% CI 
1.24 – 5.65] times more likely to use mechanical ventilation during hospitalization than non-
substance abusers. Of borderline statistical significance was flu vaccination status: those who use 
illicit drugs are 1.67 times more likely to report not receiving a flu vaccine prior to admission 
than those who do not. This result, however, had a p-value of 0.0594, and should be interpreted 
with caution. 
 Surprisingly, substance abuse was associated with a protective effect for a number of 
different health conditions, though many of the protective effects lost statistical significance after 
adjusting for age and/or smoking, where applicable. Most notably, substance abusers had 0.23 
times the odds of having coronary artery disease than non-substance abusers (p<0.05), though 
age may explain much of this relationship. 
Substance abusers exhibited the largest risks for liver disease (OR=10.79, p<0.05), HIV 
(OR=3.65, p<0.05), and AIDS (OR=30.47, p<0.05). However, due to the small number of 
individuals within the study with AIDS (n=3), results for the association with AIDS may not be 
meaningful.  
A visual representation of all statistically significant odds ratios is given in Figure 1. 
 
5.2.2 Hospitalization Epidemic Curve for Illicit Drug Abusers 
Visual comparisons between the substance abuser and non-substance abuser populations 
is difficult due to the disparity in sample size (the non-substance abuser population is nearly 15 
times larger). To better visualize the differences in a hospitalization epidemic curve, admission 
frequency totals per week were presented as proportions of the total population. The epidemic 
curve for substance abuse is presented in Figure 3. A similar epidemic curve was generated to 
compare hospital admission patterns between smokers and non-smokers; however, the curves did 
not appear significantly different (results not shown). 
The general incidence of flu-associated hospitalizations in Connecticut during 2013-2014 
follows a two-wave pattern, with the first wave peaking around MMWR weeks 4-6 (late January 
– mid February) and the second wave peaking around MMWR week 14 (April 4-11, 2014, graph 
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not shown). When hospitalization dates are stratified by substance abuse status, differences in the 
outbreak patterns emerge. Among substance abusers, the “first-wave” pattern is fairly similar, 
with a notable peak in the proportion of cases around week 2. However, hospitalization incidence 
during the “second-wave” among substance abusers is diminished, with the proportion of 
hospitalizations tapering off until MMWR weeks 16-17 (late April).  
In the general population, the second wave was marked by an increase in the proportions 
of Influenza B cases compared to Influenza A. It was hypothesized that, because substance 
abusers appeared to have less of a second wave of influenza, they may have significantly higher 
Influenza A cases. However, no association was found between flu type and substance abuse 
status, as seen in Table 1. 
 Hospitalization among substance abusers seems highest from late December through 
February. The large number of hospital admissions during MMWR week 2 (January 11-17, 
2014) represents nearly 20% of the total substance abuse population of the sample (n=12).  
 
5.2.3 Relative Risks Compared to General Population 
As seen in Table 3, substance abusers make up approximately 1.8% of the overall 
population within Connecticut. However, the proportion of substance abusers found within the 
flu-associated hospitalization population (6.34%) is considerably higher. It is estimated that 
substance abusers have a 3.53 [95% CI 2.78 – 4.51] times greater risk of being hospitalized with 
influenza than non-substance abusers within New Haven and Middlesex counties in CT.    
 
5.3 Smokers 
 Smoking status was also assessed to determine whether smoking varied by demographics 
or risk factors, and had a role in illness severity. The full results can be seen in Table 4, with 
information about the prevalence of co-morbid conditions among smokers found in Table 5. 
Variables associated with smoking were similar (but not identical) to the variables associated 
with substance abuse. The average age at time of admission for smokers was 53.7 years old, 
significantly lower than former and never smokers (72.3 and 67.1 years, respectively). Smoking 
was associated with being male (p=0.0246) and non-Hispanic black (p<0.001). 
 It is interesting to note that smoking was not significantly associated with any illness 
severity measures. Average length of stay ranged from 5.4 (±6.2) – 6.5 (±5.7) days among all 
current, former, and never smokers, and smoking status did not significantly affect survival 
outcomes of the hospitalization. Smokers also exhibited no significant differences with regards 
to vaccination status and BMI. As mentioned above, the relationship between smoking and risk 
behaviors such as alcohol and substance abuse was apparent within this population (Spearman 
correlation = 0.3152), with the majority of substance and alcohol abusers engaging in smoking as 
well.  
 
5.3.1 Logistic Regression Model for Smoking 
 To model the relationship between smoking, illness severity, risk factors, demographics, 
and co-morbid conditions among those hospitalized for influenza, a logistic regression model 
was constructed (shown in Table 6). The total sample size used in the model was 1,585 
individuals from the years 2011-2014. 
 A total of sixteen predictor variables comprised the reduced model, which had an R-
square value of 0.3408. The model satisfied the Hosmer and Lemeshow Goodness-of-Fit Test, 
which has a null hypothesis that the final model adequately fits the data. The p-value for this test 
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was 0.5628, indicating that there is not sufficient statistical information to reject the null. Pearson 
residuals exhibited a random scatter pattern about 0, with most values falling between -2 and 3, 
and very little visual indication of overdispersion.  
 The final model included age, sex, race, BMI, hospitalization outcome, ICU admission, 
length of stay, COPD, atrial fibrillation, congestive heart failure (CHF), immunosuppressed 
status, HIV, renal disease, and liver disease as predictors, with one interaction term between age 
and CHF. From the model, odds ratios and 95% confidence intervals were obtained. 
 Many of the effects in the model were slight: those who were older had 0.95 [95% CI 
0.94 – 0.96] times the odds of being a smoker than younger individuals, and those with heavier 
BMIs had 0.98 [95% CI 0.96 – 0.99] times the odds of being a smoker. Smoking was 
significantly more common in males, and non-Hispanic blacks had 1.81 [95% CI 1.29 – 2.53] 
times the odds of being smokers than non-Hispanic whites. Hispanics did not have a statistically 
significant increase in the probability of being a smoker when compared to non-Hispanic whites. 
Additionally, hospitalization survival outcomes, ICU admission, and length of stay, while 
included in the model, were not statistically significant predictors of smoking. 
 Smokers were shown to be at increased risk for several disease conditions: they had 2.42 
[95% CI 1.34 – 4.36] times the odds of having liver disease compared to non-smokers, 3.70 
[95% CI 1.60 – 8.52] times the odds of being HIV positive, and 4.34 [95% CI 3.17 – 5.95] times 
the odds of having COPD.  Within this population, smoking represented an enormous risk for 
congestive heart failure (CHF), with smokers being 41.67 [95% CI 3.92 – 442.95] times as likely 
to have CHF than non-smokers. However, the wide range in the confidence interval indicates 
that this odds ratio may not reflect a risk of that magnitude, so this result is to be interpreted 
cautiously. 
 Smoking also appeared to be slightly protective against atrial fibrillation (OR=0.40, 95% 
CI 0.18 – 0.89), having immunosuppressed status (OR=0.51, 95% CI 0.35 – 0.74), and renal 
disease (OR=0.61, 95% CI 0.40 –0.94). All statistically significant odds ratios from the smoking 
regression model are displayed in Figure 4. 
 
5.3.2 Relative Risks Compared to General Population and Substance Abusers 
The relative risk of flu-associated hospitalization for smokers is presented in Table 6. 
Smokers make up approximately 18.4% of the overall population within Connecticut, and 26.7% 
of the 2013-2014 hospitalized influenza population. Smokers have a 1.72 [95% CI 1.55 – 1.92] 
times greater risk of being hospitalized with influenza than nonsmokers within New Haven and 
Middlesex counties in CT, assuming an even distribution of smokers throughout the state.    
 
6. DISCUSSION 
 
6.1 Study Findings 
The disease burden due to influenza annually results in millions of dollars in lost 
productivity, millions of hospitalized days, and morbidity and mortality due to severe infection 
and co-infection. This study offers a descriptive analysis of the burden of influenza among those 
with high risk behaviors, a group not often studied with regards to influenza infection.  
It is important to contextualize the findings in light of a few underlying factors of the 
study design. First, the population captured in the study are those who were hospitalized with 
influenza. This does not guarantee that an individual was hospitalized due to influenza infection; 
there may be additional or other reasons that explain hospital admission. However, it is 
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reasonable to assume that the majority of severe influenza cases requiring hospitalization are 
contained within the study population. 
Second, there was the potential of misclassification as a result of the categorization 
methods used in the 2013-2014 season. The data collection form used for the retrospective chart 
reviews did not have a specified place to mark drug abuse status, and results were dependent 
upon the chart reviewer indicating drug use/abuse under the “Other conditions, Other” category. 
Cases of substance abuse may have been missed due to failure to indicate status on the collection 
form, failure for the physician to make a note of substance abuse on the medical chart, or 
concealment of substance abuse status by the patient. It is possible that incidence of substance 
abuse could be higher among the influenza-associated hospitalized population, which indicates 
that the relative risk of hospitalization may be underestimated in this study. 
Lastly, estimations of risk and illness severity may be confounded by the way substance 
abusers interact with the health system itself. Substance abusers with no desire to enter 
rehabilitation are often an isolated population, who may be less likely to seek medical care for 
serious conditions due to fear of discovery or withdrawal. One partial indicator for delay in 
seeking care is the receipt of antivirals. Oseltamivir (Tamiflu), the primary antiviral administered 
for flu in Connecticut, is recommended for those who present within 48 hours of first symptom 
onset. After the 48 hour window, it is up to physician discretion to administer, but generally 
regarded as less effective and unadvisable [42]. A significantly lower prescription rate among 
substance abusers may indicate more substance abusers being admitted past the 48 hour window 
when compared to the general population, though this is not an exact proxy due to variations in 
prescription patterns. Both the substance abuser and smoker populations displayed nearly 
identical proportions of oseltamivir treatment as the general hospitalized population, indicating 
no difference in treatment patterns. It is possible that substance users may wait to go to the 
emergency room due to influenza and associated complications until problems become too 
significant to ignore, resulting in fewer substance abusers being captured within this population. 
On the other hand, avoidance of the health system may result in poorer health outcomes once 
substance abusers are hospitalized. This could partially explain the increased risk of ICU 
admission and mechanical ventilation seen among substance abusers. 
Even with these factors taken into consideration, the substance abuser population is 
unique in many ways. 72.5% of the hospitalizations among substance abusers can be attributed to 
drug abuse, and substance abusers have a substantially increased risk of being hospitalized 
compared to the general population. Within the influenza-hospitalized population, substance 
abuse was also more common among minority demographic groups. The National Survey on 
Drug Use and Health found no significant differences in substance abuse prevalence across race 
[16], yet non-Hispanic blacks and Hispanic substance abusers were hospitalized at higher 
proportions than non-Hispanic whites. This could point to other socioeconomic differences at 
play among substance abusers that were not measured in this study. Although females in the 
general population are at higher risk for influenza, there was a far greater proportion of male 
substance abusers hospitalized than females. The significant gender gap in drug use reflects the 
national trends that males are more likely to report smoking and substance use than females [33].  
Furthermore, substance abusers appeared to be less likely to have a flu vaccine than the 
general population hospitalized for influenza, which may be related to substance abusers’ 
reluctance to interact with the health system, as discussed above. Another possible reason for 
lower vaccination rates could be missed vaccination opportunities through workplace or school-
based clinics. A prior study on vaccination rates among the elderly reported that cigarette 
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smoking was associated with decreased likelihood of vaccination [39]. While this may factor into 
the decreased vaccination coverage among substance abusers—of whom a large number happen 
to be smokers—it does not explain the fact that smoking status had no association with flu 
vaccination status within this study population.   
 A considerable distinguishing factor of substance abusers is the chronological pattern of 
hospitalizations compared to non-substance abusers.  The large spike in cases in MMWR week 
#2, in which 20% of the substance abuser population was hospitalized, may indicate connections 
within the community, or a larger outbreak among substance abusers during that time. The study 
did not have the ability to discern whether or not there were social ties between various members 
of the substance abusing population, but it is possible that transmission patterns may vary based 
on social network connections. More research is needed to determine if these patterns are related 
to social interactions.  
 Another factor of concern is the significantly earlier age upon hospital admission seen 
among substance abusers. Given that the prevalence of chronic diseases increases and immune 
function decreases generally as the population ages, it is expected that a greater number of 
elderly individuals will experience more severe cases of influenza, resulting in hospitalization. 
However, it appears that substance abuse contributes to being hospitalized at a substantially 
younger age (average age upon hospitalization among substance abusers = 52.4 years, compared 
to 66.4 for non-substance abusers).  
The increased illness severity among substance abusers may be partially explained by the 
connection between immunodeficiency and drug abuse.  It is generally well established that 
injection drug users exhibit a decrease in immune function and are at increased risk for 
conditions such as HIV and HBV [34]. These findings are supplemented by the increased risk for 
HIV, AIDS, and immunocompromised status among substance abusers in the study population.  
Taken with the evidence and comparisons drawn above, it appears that substance abuse 
may have at least a partial role in increasing the likelihood of influenza-associated 
hospitalization, and the severity of the illness once hospitalized. This increased risk, combined 
with the decreased likelihood of substance abusers to receive flu vaccines, results in a higher 
burden of disease due to influenza among substance abusers within Connecticut. 
 
It is interesting to note that smokers did not exhibit the same increases in illness severity. 
While the smoking population shared similar demographic risk factors as substance abusers 
(more likely to be male, non-Hispanic black, and younger age upon admission), it appears that 
smokers do not differ much from the general population when it comes to severe influenza. The 
relative risk of acquiring influenza severe enough to be hospitalized is moderate (RR=1.72). This 
is affirmed by the extensive literature on smoking’s associations with increased severity of 
respiratory illnesses, though this relative risk is less than half the risk for influenza-associated 
hospitalizations seen among substance abusers.    
It is possible that some of the associations seen between health conditions and smoking 
found in the logistic regression model are confounded by other risk behaviors. Analysis from the 
2013-2014 substance abuser population indicated that substance abusers also have an increased 
risk of HIV—this may point to an overestimation of HIV risk due to the tight overlap between 
the substance abuse and smoker population, and the necessary exclusion of substance abuse from 
the model. It is also possible that alcohol abuse, another variable not included but tightly 
correlated with smoking, could explain part of the elevated risk of liver disease. 
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Overall, smokers exhibited a different course of illness and different disease profile. Perhaps 
the most significant difference between the smoking and substance abuse populations were the 
effects of illness severity—smoking did not have any associations with measures of severity, 
while substance abuse seemed to cause increased burden of illness. The comparison between 
associations provides grounds for treating smokers and substance users as two separate risk 
groups with differing health needs, despite the large number of substance abusers who also 
smoke. 
 
6.2 Limitations 
 
Size 
 First, the small sample size of substance abusers (n=61) prevented the use of more 
rigorous statistical testing due to low power. Previous years of influenza surveillance data did not 
collect drug use status upon case hospitalization, which also prevented the use of multi-year data 
to conduct further analysis. However, the 2014-2015 influenza season data collection includes 
intravenous drug use as a health condition category, ensuring more rigorous quantification of the 
population in future years.     
 
Generalizability 
The population studied was limited to the relatively small area of New Haven and 
Middlesex counties, Connecticut. Within New Haven County, the population is 65.8% non-
Hispanic white, 14.0% non-Hispanic black, and 16.4% Hispanic, whereas Middlesex County is 
85.2% non-Hispanic white, 5.3% non-Hispanic black, and 5.5% Hispanic, with other races 
making up the remaining population in both counties [32]. The study population (64.1% non-
Hispanic white, 20.8% non-Hispanic black, 12.0% Hispanic, 3.1% other) closely resembles the 
demographics of New Haven County, indicating that the study provides a fairly proportional 
race/ethnicity representation. The race demographics are not too far off from the U.S. as a whole, 
which reports 62.6% non-Hispanic whites, 13.2 non-Hispanic blacks, and 17.1% Hispanics [43]. 
However, the age distribution of the study population is skewed toward the elderly, and has a 
higher proportion of females represented when compared to males. There is the possibility that 
the differences in these baseline demographics, as well as any unmeasured demographic 
variables, may not be generalizable to the rest of the United States.  
 
Confounding   
The overlap between the smoking and substance abuser populations is of considerable 
concern for confounding within the data, particularly for co-morbid conditions. Smoking is 
linked to a number of adverse health outcomes, including increased incidence of respiratory 
infections, chronic lung conditions, and heart disease. Examining the individual impacts of each 
risk behavior side by side, along with smoking-adjusted odds ratios, allows for a clearer picture 
to emerge. 
 Evidence indicates that tobacco smokers—especially those who begin smoking during 
childhood and adolescence—have an increased risk for using substances throughout their 
lifetime [35, 36].  
It is important to note that smoking status was not significantly associated with any 
disease severity measures in the study, while substance abuse status was. It appears that, while 
smoking may contribute to adverse health outcomes in general, within this population the added 
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burden of substance abuse increases illness severity, indicating that substance abusers have 
unique health needs. 
 
Age  
Age was an effect modifier in this study. As the population ages, risk of illness increases: 
according to the North American Association of Central Cancer Registries, aging is associated 
with increased risk of many cancers, including lung, colon, breast and prostate cancers [37]. 
Over half of all U.S. adults over the age of 65 are affected by conditions such as arthritis and 
hypertension. One in three are affected with heart disease, and one in five have diabetes [38]. 
Due to low sample size among the substance abuser population, there was not enough statistical 
power to significantly detect differences across age strata. However, the low number of elderly 
(70+) substance abusers may have affected the associations between substance abuse and certain 
co-morbid conditions. The protective effects seen among substance abusers for diseases such as 
coronary artery disease and congestive heart failure could be due to the fact that substance 
abusers were, on average, eight years younger than the rest of the hospitalized population. 
 However, the fact that substance abusers were far younger upon hospitalization may 
point to the burden of substance abuse. Influenza-associated hospitalizations are far more 
common among the elderly; it is possible that the act of substance abuse itself contributes to 
earlier hospitalization times among the substance abuse population, rather than any age-
associated co-morbid conditions. 
 
6.3 Implications and Future Directions 
 The findings of this study indicate that substance abusers—and to a lesser extent, 
smokers—have unique health needs when it comes to severe cases of influenza. Current 
interventions and impact studies often ignore neglected and hidden populations such as substance 
abusers; however, this study indicates that substance abusers may need extra public health 
measures to lessen the burden of sever influenza among the population. 
More studies should be conducted to further investigate relationships between influenza 
severity and drug use. As multiple years of data on substance users becomes available, studies 
can be undertaken with larger sample sizes to verify the associations observed in this project. 
Additionally, Connecticut data can be compared to data from other Emerging Infections Program 
surveillance sites to see whether the substance user population differs across states. 
For surveillance purposes, it may be useful to keep track of the time of hospitalization 
among substance abusers. Weeks or periods with larger-than-average numbers of hospital 
admissions for this population may point to community-based outbreaks. 
Additionally, the decreased vaccination coverage seen among substance abusers could 
inform future public health efforts. Flu vaccination campaigns may be designed to be more 
accessible to substance abusers, such as incorporating opt-out vaccine scheduling at existing 
needle exchange programs or drug treatment programs to ensure higher rates of vaccination.  
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7. APPENDIX 1. 
 
Table A.1 List of health conditions assessed. 
Condition  
Asthma Plegias/paralysis 
Any chronic lung disease Seizure/Seizure disorder 
Cystic fibrosis Immunocompromised status 
Emphysema/COPD AIDS 
Any chronic metabolic disease HIV 
Diabetes Cancer, in treatment or diagnosed in last 12 months 
Thyroid dysfunction Complement deficiency 
Sickle cell disease Immunoglobulin deficiency 
Splenectomy/Asplenia Immunosuppressive therapy 
Thrombocytopenia Organ transplant 
Hemoglobinopathy Stem cell transplant 
Atherosclerotic cardiovascular disease (ASCVD) Steroid therapy within 2 weeks of admission 
Any cardiovascular disease Any renal disease 
Cerebral vascular incident/stroke Chronic kidney disease  
Congenital heart disease End stage renal disease/Dialysis 
Coronary artery disease Glomerulonephritis 
Heart failure/CHF Nephrotic syndrome 
Any neuromuscular disorder Liver disease 
Duchenne muscular dystrophy Systemic lupus 
Muscular dystrophy Morbidly obese 
Multiple sclerosis Obese 
Mitochondrial disorder Pregnant 
Myasthenia gravis Post-partum 
Any neurologic disorder Dementia 
Cerebral palsy Developmental delay 
Cognitive dysfunction Down syndrome 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
33 
 
APPENDIX 2. 
Relationship between age, substance abuse, and health conditions. 
 
 The age distribution of the substance abuse population vs. the non-substance abuse 
population is depicted in Figure 2. Nearly half of all substance abusers (n=29, 47.5%) are aged 
50-59 years. There was only 1 case under the age of 30, and only 1 over the age of 70.  
 To depict the general relationship between age and the various health conditions, 
correlation coefficients are listed in Table A.2 below. Younger age was associated with asthma, 
smoking, substance abuse, HIV, and having an increased BMI. Older age was associated with 
atrial fibrillation, coronary artery disease, congestive heart failure, thyroid dysfunction, and renal 
disease. Very weak to insignificant correlations were seen between liver disease, AIDS, and 
immunosuppressed status. 
 This may help to explain the protective effect seen in the associations between substance 
abuse and coronary artery disease, and metabolic diseases (thyroid dysfunction, diabetes). 
However, it is also difficult to discern how much of disease onset in this population is due to 
aging or engagement in risk behaviors such as smoking and substance use. 
 
Table A.2. Correlation between age and select conditions. 
 
Condition Correlation with Age (Pearson) p 
Asthma -0.2879 <0.001 
Smoking -0.3472 <0.001 
Substance Abuse -0.1807 <0.001 
Atrial Fibrillation 0.3028 <0.001 
Coronary Artery Disease 0.2806 <0.001 
Congestive Heart Failure 0.2493 <0.001 
Thyroid Dysfunction 0.2399 <0.001 
Renal Disease 0.1598 <0.001 
Immunosuppressed Status -0.0864 0.0074 
AIDS -0.0454 0.1597 
HIV Positive -0.1002 0.0019 
Neurological disorder -0.1167 <0.001 
Liver Disease -0.0717 0.0263 
BMI -0.1805 <0.001 
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